Phase 2 Neuroendocrine Tumor Clinical Trials
49 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 49 trials
Recruiting
Phase 2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Unresectable Digestive System Neuroendocrine Tumor G1Unresectable Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)100 enrolled39 locationsNCT05773274
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Breast CancerOvarian CancerProstate Cancer+6 more
University of Florida29 enrolled1 locationNCT05000294
Recruiting
Phase 2
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting
Phase 2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Phase 2
CapTemY90 for Grade 2/3 NET Liver Metastases
Neuroendocrine TumorsNeuroendocrine Tumor Grade 2
Abramson Cancer Center at Penn Medicine70 enrolled4 locationsNCT04339036
Recruiting
Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Breast CancerOvarian CancerNon-small Cell Lung Cancer+4 more
National Cancer Institute (NCI)285 enrolled1 locationNCT03412877
Recruiting
Phase 1Phase 2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor+1 more
Fox Chase Cancer Center111 enrolled1 locationNCT05263050
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled24 locationsNCT07129252
Recruiting
Phase 2
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Neuroendocrine Tumors
University of Alberta600 enrolled1 locationNCT04888481
Recruiting
Phase 2
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2Phase 3
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting
Phase 1Phase 2
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Hepatocellular CarcinomaNeuroendocrine TumorsGastrointestinal Cancer Metastatic
Teclison Ltd.25 enrolled2 locationsNCT02174549
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755